S1051
Clinical – Sarcoma, skin cancer, malignant melanoma
ESTRO 2026
sarcoma
Digital Poster 4668
Real-world outcomes of Cemiplimab in advanced cutaneous squamous cell carcinoma: a single- center audit of over 100 patients Venga Vengadasalam, Rebecca Shakir, Nicholas Coupe, Miranda Payne, Ben Fairfax, Amanda Salisbury, Matthew Potter, Sinclair Gore, Oliver Cassell, Roman Mykula, Richard Turner, John Reed, Chris Phillips, Stephanie Arnold, Gorav Wali Oncology, Churchill Hospital, Oxford University Hospitals Trust, Oxford, United Kingdom Purpose/Objective: While most Cutaneous squamous cell carcinomas (cSCC) are curatively treated with surgery and/or radiotherapy, a considerable proportion of patients present with disease not radically treatable. Cemiplimab, a PD1 inhibitor, revealed high response rates and sustained benefit in pivotal phase II trials, leading to both EMA and NICE approval in 2019 for patients who were unsuitable for curative treatment. Evidence in real-world populations remains limited, especially in groups not represented in initial trials, including older patients with poor performance status(PS), significant comorbidities including autoimmune conditions and history of solid organ transplantation. The aim of this study was to evaluate outcomes of patients with advanced cSCC treated to date in our centre with Cemiplimab. Material/Methods: A retrospective audit was performed using local hospital electronic prescribing systems to identify all patients treated with Cemiplimab between 2019-2025. Baseline demographics, ECOG PS, disease site, transplant history, treatment details and toxicities were extracted from the electronic patient record (EPR). Outcomes evaluated included overall response rate, disease control rate, progression free survival (PFS), overall survival (OS). Survival analyses were conducted using Kaplan Meier curves. Results from the audit were compared with initial trials[1]and real world data*[2][3]. Results: Results:A total of 102 patients were included. The 5- year-PFS was 67.1%(95%CI 54.3–82.8%), which was consistent with or exceeded published outcomes. 5- year-PFS-rate:67.1%(95%CI54.3–82.8%)
Patients with locally advanced disease derived greater benefit compared with those with metastatic disease
(5-year-PFS 81%vs54.9%). 5-year-PFS- rate:81%(95%CI68.2–96.3 %)5-year-PFS- rate:54.9%(95%CI38.4–78.6%)
All cause OS was 58.6% (95%CI 47.7–72.0%), and disease-specific OS was 80.9%, with correlation between outcomes and PS. Head-and-neck primaries demonstrated superior outcomes compared with limb primaries. Three renal transplant recipients with metastatic disease achieved durable responses (two partial, one complete), with immune-related adverse events including nephritis and bullous pemphigoid, but notably without graft rejection. Detailed toxicity analysis is pending but demonstrates manageable safety profiles in most patients. Conclusion: This large single-centre study in a real-world population confirms that Cemiplimab is an effective treatment for advanced cSCC, with outcomes comparable to or exceeding trial results. Durable disease control was observed across subgroups, including patients with significant comorbidities and organ transplants, who achieved sustained benefit without graft rejection. There was greater benefit in locally advanced disease compared to metastatic disease, and head and neck primaries sustained better response than limb primaries. Overall, the data supports the use of Cemiplimab and emphasise the importance of widening evidence involving underrepresented populations. References: [1] Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with
Made with FlippingBook - Share PDF online